Kiora’s KIO-300 Shows p<0.0001 Seizure Activity Suppression in Preclinical Model
KPRX•KIO-300, part of Kiora Pharmaceuticals’ ion channel modulator platform, produced sustained suppression of epileptiform activity in mouse hippocampal slices, with statistically significant inhibition beginning 42 minutes after treatment (p<0.0001) and persisting through washout. It reduced cumulative epileptiform burden without impairing normal neural transmission, suggesting potential CNS applications beyond vision.
1. Preclinical Efficacy Data
KIO-300 significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model using mouse hippocampal CA1 slices. Treated tissues showed a clear reduction in spontaneous epileptiform event frequency compared with vehicle controls, demonstrating the compound’s direct impact on abnormal neural firing.
2. Statistical Significance and Duration
Statistically significant inhibition of epileptiform events began 42 minutes after KIO-300 administration (p<0.0001), with cumulative epileptiform burden also markedly reduced (p<0.0001). The suppressive effect persisted through both treatment and washout periods, and normal electrical transmission across neural tissue remained unaffected.
3. Platform Expansion and Future R&D
Building on earlier findings of approximately 50% reduction in retinal hyperactivity, Kiora will pursue translational R&D efforts to optimize molecular modifications and delivery strategies for epilepsy and other neurological indications. The company retains full development and commercialization rights for applications beyond ophthalmology.
